Previous 10 | Next 10 |
Accelerated pace of enrollment supports speed to market strategy Topline results from Stage 1 expected to be presented in the second quarter of 2024 followed by Stage 2 data in the third quarter of 2024 SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasda...
SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Execut...
Speed to market strategy for Nana-val in patients with relapsed or refractory EBV + peripheral T-cell lymphoma supported by complete enrollment of Stage 1, complete enrollment of Stage 2 anticipated in Q1 2024 and engagement with the FDA on potential accelerated approval pathway by mi...
2023-12-12 11:14:57 ET More on Viracta Therapeutics Viracta Therapeutics GAAP EPS of -$0.33 misses by $0.03 Seeking Alpha’s Quant Rating on Viracta Therapeutics Historical earnings data for Viracta Therapeutics Financial information for Viracta Therape...
First orphan drug designation for Nana-val granted in EBV + solid tumors Seventh orphan drug designation for Nana-val globally; fifth granted by the FDA SAN DIEGO, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision onc...
Confirmed partial responses without dose-limiting toxicities during dose escalation along with new preclinical data support the opportunity to further enhance efficacy through a novel split daily dosing regimen at higher dose levels of Nana-val Enrollment is underway for the sixth dose ...
2023-11-09 08:57:42 ET More on Viracta Therapeutics Seeking Alpha’s Quant Rating on Viracta Therapeutics Historical earnings data for Viracta Therapeutics Financial information for Viracta Therapeutics For further details see: Viracta Therapeutics ...
Reported preliminary clinical data from the pivotal NAVAL-1 clinical trial of Nana-val in patients with relapsed or refractory EBV + peripheral T-cell lymphoma showing an overall response rate and complete response rate of 40% Reported interim data from the Phase 1b/2 trial ...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Viracta Therapeutics Inc. (VIRX) is expected to report $-0.33 for Q3 2023
News, Short Squeeze, Breakout and More Instantly...
Viracta Therapeutics Inc. Company Name:
VIRX Stock Symbol:
NASDAQ Market:
Viracta Therapeutics Inc. Website:
SAN DIEGO, May 17, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that, in connection with the appointment of Mi...
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced the appointment of Michael Faerm as Chief Financia...